Understanding the Cautions and Contraindications of Immunomodulator and Biologic Therapies for Use in Inflammatory Bowel Disease
Authors:
Open Access
- 1 August 2017
- journal article
- review article
- Published by Oxford University Press (OUP) in Inflammatory Bowel Diseases
- Vol. 23 (8) , 1301-1315
Abstract
Ulcerative colitis and Crohn's disease are chronic inflammatory bowel diseases for which there are no cures. These diseases are immunopathogenic, andKeywords
This publication has 174 references indexed in Scilit:
- Vedolizumab as Induction and Maintenance Therapy for Crohn's DiseaseNew England Journal of Medicine, 2013
- Vedolizumab as Induction and Maintenance Therapy for Ulcerative ColitisNew England Journal of Medicine, 2013
- Intrauterine exposure and pharmacology of conventional thiopurine therapy in pregnant patients with inflammatory bowel diseaseGut, 2013
- Increased Risk of Pneumonia Among Patients With Inflammatory Bowel DiseaseAmerican Journal of Gastroenterology, 2013
- Association of Crohn’s Disease, Thiopurines, and Primary Epstein-Barr Virus Infection with Hemophagocytic LymphohistiocytosisThe Journal of Pediatrics, 2011
- Methotrexate-induced pneumonitis in Crohn's disease. Case report and review of the literatureMultidisciplinary Respiratory Medicine, 2010
- Mutagenicity and Potential Carcinogenicity of Thiopurine Treatment in Patients with Inflammatory Bowel DiseaseCancer Research, 2009
- Fertility and Reproduction in Male Patients with Ankylosing Spondylitis Treated with Infliximab: Table 1.The Journal of Rheumatology, 2009
- A meta-analysis on the influence of inflammatory bowel disease on pregnancyGut, 2006
- Treatment of Crohn's Disease with 6-MercaptopurineNew England Journal of Medicine, 1980